Digital Library
Close Browse articles from a journal
 
Search for with title:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Journal description
       All volumes of the corresponding journal
         All issues of the corresponding volume
                                       All articles of the corresponding issues
 
                             131 results found
no title author magazine year volume issue page(s) type
1 AA genotype of deSNP rs6726639 of MERTK gene is associated with development of Hepatocellular Carcinoma after eradication of Hepatitis C Virus infection Di Marco, L.
 2019
 51 S1 p. e7
 article
2 Accuracy of diagnostic evaluation of hepatocellular carcinoma with LI-RADS Barabino, M.
 2019
 51 S1 p. e41
 article
3 A close monitoring of virological and immunological hepatitis B markers can improve the diagnosis of HBV reactivation in HBsAg-negative/anti-HBc-positive patients with oncohematological diseases Salpini, R.
 2019
 51 S1 p. e67
 article
4 Acquisition of stem-like features in human cholangiocarcinoma is associated with an oxidative metabolism Raggi, C.
 2019
 51 S1 p. e34
 article
5 Acute presentation and male predominance in a series of adult patients with seronegative autoimmune hepatitis Bensi, C.
 2019
 51 S1 p. e20
 article
6 AGT gene polymorphisms predict early dose modification of sorafenib for dermatological adverse events: towards tailored medicine for patients with hepatocellular carcinoma Iavarone, M.
 2019
 51 S1 p. e38
 article
7 A.I.S.F. 2019: Abstracts evaluation procedure 2019
 51 S1 p. e70
 article
8 Algorithms using noninvasive tests can accurately identify patients with advanced fibrosis due to NASH: data from the STELLAR clinical trials Lampertico, P.
 2019
 51 S1 p. e25-e26
 article
9 Alterations in stearoyl-CoA-desaturase index and metalloproteinase activity in nutritional versus genetic rat models of NAFLD Siciliano, V.
 2019
 51 S1 p. e31
 article
10 A new regulator of mitochondrial OXPHOS in hepatocytes and HCC cell lines: the AAA+ ATPase RuvBL1 Simeone, I.
 2019
 51 S1 p. e39
 article
11 An intention-to-treat competing-risk model for candidates with hepatocellular cancer waiting for liver transplantation Lai, Q.
 2019
 51 S1 p. e13
 article
12 Association between black race and presentation and liver-related outcomes of patients with autoimmune hepatitis de Boer, Y.S.
 2019
 51 S1 p. e18-e19
 article
13 ATG7 genetic variant and defective autophagy: a novel risk factor for non-alcoholic fatty liver disease progression in patients with type 2 diabetes mellitus Pelusi, S.
 2019
 51 S1 p. e4-e5
 article
14 Can we revise Baveno VI criteria using spleen elastography? Giuffrè, M.
 2019
 51 S1 p. e45
 article
15 Capecitabine in advanced hepatocellular carcinoma: a multicenter experience Pelizzaro, F.
 2019
 51 S1 p. e40
 article
16 Changes in 13C-aminopyrine breath test predict liver-related events and death in patients with HCV-related previous decompensated child A5 or child A6 to B cirrhosis who achieve SVR after DAA therapy Petta, S.
 2019
 51 S1 p. e68
 article
17 Characteristics of hepatocellular carcinoma patients with long-term survival: an ITA.LI.CA report Pelizzaro, F.
 2019
 51 S1 p. e38
 article
18 Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance Barbaliscia, S.
 2019
 51 S1 p. e65-e66
 article
19 Characterizing compensated cirrhosis (CC) patients with potential etiology of nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH): findings from large Italian administrative databases Marchesini, G.
 2019
 51 S1 p. e49-e50
 article
20 Chemokine changes during direct antiviral agents (DAA) therapy in patients with HCV infection or reinfection after liver transplantation: preliminary insights on their possible correlates Colucci, G.
 2019
 51 S1 p. e66
 article
21 Cholangiocarcinoma primary, circulating and metastatic stem-like cells Correnti, M.
 2019
 51 S1 p. e32
 article
22 Circulating miR-3185 as a predictive marker for overall survival in patients with hepatocellular carcinoma Pratama, M.Y.
 2019
 51 S1 p. e36
 article
23 Clinical but not genetic variables predict the development of hepatocellular carcinoma in hepatitis C cirrhotic patients treated with direct acting antivirals: a 3-year study in 509 patients Degasperi, E.
 2019
 51 S1 p. e67
 article
24 Clinical impact of comorbidities in an Italian NAFLD cohort Miele, L.
 2019
 51 S1 p. e32
 article
25 Clinical presentation and etiological spectrum of idiopathic non-cirrhotic portal hypertension (INCPH): data from the Italian Registry Primignani, M.
 2019
 51 S1 p. e49
 article
26 Combined therapy with Sorafenib and FAK inhibitor TAE226 impairs hepatocellular carcinoma growth by interfering with epigenetic modifications and stemness markers Romito, I.
 2019
 51 S1 p. e36
 article
27 De novo neoplasms after liver transplantation: donor gender and age influence Shalaby, S.
 2019
 51 S1 p. e50
 article
28 Development of a model based on case-mix analysis to predict 6-month patient survival after liver transplantation: a multicenter Italian study Avolio, A.
 2019
 51 S1 p. e11-e12
 article
29 Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients Cabibbo, G.
 2019
 51 S1 p. e36-e37
 article
30 Ductular reaction, intermediate hepatocytes and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis Cristoferi, L.
 2019
 51 S1 p. e1
 article
31 Early referral to transplant centers is a prognostic factor influencing outcomes of pediatric liver transplantation Angelico, R.
 2019
 51 S1 p. e53
 article
32 Early treatment with sorafenib and mTOR inhibitor in recurrent hepatocellular carcinoma after liver transplantation: safety and survival Mazza, S.
 2019
 51 S1 p. e35
 article
33 Editorial Board 2019
 51 S1 p. i-ii
 article
34 Effectiveness and safety of Sofosbuvir/Velpatasvir/Voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: a real-life study from the Navigatore Lombardia and Veneto Networks Degasperi, E.
 2019
 51 S1 p. e15
 article
35 Effectiveness, safety and T-cell activation profiles of long-term Myrcludex B treatment in two patients with HDV related compensated cirrhosis Loglio, A.
 2019
 51 S1 p. e62
 article
36 Effects of DAAs (direct-acting antivirals) on cardiac function and structure in hepatitis c (HCV) patients with low-mild liver fibrosis Dalbeni, A.
 2019
 51 S1 p. e58
 article
37 Effects of HCV eradication by DAA on oxidative stress parameters in patients with chronic hepatitis C Salomone, F.
 2019
 51 S1 p. e59
 article
38 Efficacy and safety of Elbasvir/Grazoprevir in a large real-life cohort of HCV-infected patients Gambato, M.
 2019
 51 S1 p. e55-e56
 article
39 Epidemiology of porphyrias in Italy: rare complex diseases with liver involvement- data from the registry of Gruppo Italiano Porfiria (GrIP) Ventura, P.
 2019
 51 S1 p. e20
 article
40 Extracellular vesicles derived from CHK2 mRNA as a possible predictive marker of HCC in HCV-infected patients Cavallini, L.
 2019
 51 S1 p. e58
 article
41 Extra-hepatic tumor recurrence after directly-acting-antiviral (DAA) therapy in HCV patients Torres, M.C. Plaz
 2019
 51 S1 p. e63
 article
42 Fondaparinux vs low molecular weight heparin in the treatment of non malignant portal vein thrombosis in patients cirrhosis Senzolo, M.
 2019
 51 S1 p. e42
 article
43 FXR rs35724 G>C variant modulates cholesterol levels, carotid atherosclerosis and liver damage in non-alcoholic fatty liver Grimaudo, S.
 2019
 51 S1 p. e26
 article
44 Ganglioside composition correlates with the malignant phenotype of cholangiocarcinoma cells and modulates cell adhesion Mannini, A.
 2019
 51 S1 p. e7
 article
45 HCV-Ab sero-prevalence in persons who inject drugs in a Province of Southern Italy: results of a screening program De Luna, A.
 2019
 51 S1 p. e17
 article
46 Hepatitis C virus prevalence in a cohort of jailbirds in a city of Southern Italy Caruso, R.
 2019
 51 S1 p. e59
 article
47 Hepatocyte expression of the protein kinase ERK5 regulates insulin sensitivity Di Maira, G.
 2019
 51 S1 p. e28
 article
48 Hepatocyte-specific deletion of ERK5 modulates liver regeneration in mice Di Maira, G.
 2019
 51 S1 p. e43
 article
49 HEV infection: an emerging disease. One year observation in a tertiary care center in Milan De Nicola, S.
 2019
 51 S1 p. e24
 article
50 Human duodenal submucosal glands contain stem cells with potential for liver and pancreatic regenerative medicine Carpino, G.
 2019
 51 S1 p. e3
 article
51 Immunomorphological and molecular panel help identify intermediate cells in mixed primary liver cancers Malvi, D.
 2019
 51 S1 p. e35
 article
52 Impact of diastolic dysfunction (LVDD) on clinical response and prognosis after transjugular intrahepatic portosystemic shunt (TIPS) for refractory ascites Venon, W. Debernardi
 2019
 51 S1 p. e11
 article
53 Impact of genetic polymorphisms associated with NAFLD on hepatic and vascular complications in diabetes Lombardi, R.
 2019
 51 S1 p. e28-e29
 article
54 Impact on post liver transplant outcomes of response to treatment with terlipressin and albumin in patients with hepatorenal syndrome Vettore, E.
 2019
 51 S1 p. e50-e51
 article
55 Incidence and outcome of portal vein thrombosis in 817 HBV and HCV cirrhotic patients under antiviral treatment: a single center longitudinal study Tosetti, G.
 2019
 51 S1 p. e10
 article
56 Incidence and prognostic factors of “de novo” development/worsening of esophageal varices in HCV-related chronic advanced liver disease after sustained virologic response achieved by direct oral antiviral agents Tosetti, G.
 2019
 51 S1 p. e47
 article
57 Increased portal pressure is associated with elevated liver enzymes during pregnancy: the role of doppler-ultrasound and liver stiffness measurement Serra, C.
 2019
 51 S1 p. e22-e23
 article
58 Indocyanine green retention test predict the risk of portal hypertension-related events after direct-acting antiviral therapy in compensated advanced chronic liver disease patients Ravaioli, F.
 2019
 51 S1 p. e55
 article
59 INOS-mediated decrease of matrix metalloproteinase activity by obeticholic acid in hepatic ischemia/reperfusion Di Pasqua, L.G.
 2019
 51 S1 p. e45
 article
60 Is poor vitamin status a reliable target for treatment of symptomatic patients with hepatic acute porphyrias? Ventura, P.
 2019
 51 S1 p. e23-e24
 article
61 Key mutations in HBsAg C-terminus correlate with lower HBsAg levels in vivo, hinder HBsAg release in vitro and affect HBsAg structural stability in HBeAg-negative chronic HBV genotype D infection Piermatteo, L.
 2019
 51 S1 p. e60
 article
62 Lack of CCL2 limits the development of HCC in a model of obesity-associated carcinogenesis Vivoli, E.
 2019
 51 S1 p. e34
 article
63 Laparoscopic liver resection versus transarterial chemoembolization for hepatocellular carcinoma in BCLC B patients: a propensity score analysis Bertacco, A.
 2019
 51 S1 p. e13
 article
64 Laparoscopic liver resection versus transarterial chemoembolization for hepatocellular carcinoma in child B cirrhosis: a propensity score analysis Bertacco, A.
 2019
 51 S1 p. e52
 article
65 Liver stiffness-spleen size-to-platelet ratio risk score (LSPS) detects esophageal varices and HCC risk in HCV- and HBV-related cirrhosis responsive to DAA Imperatrice, B.
 2019
 51 S1 p. e48
 article
66 Longitudinal prognostic value of the most common algorithms for fibrosis in non-alcoholic fatty liver disease. An international study in non-cirrhotic, biopsy-proven patients Younes, R.
 2019
 51 S1 p. e5
 article
67 Long-term albumin administration in patients with cirrhosis and uncomplicated ascites: the use of serum albumin concentration for personalizing treatment Zaccherini, G.
 2019
 51 S1 p. e9
 article
68 Long-term liver function changes and related risk factors after direct-acting antiviral therapy in HCV-infected cirrhotic patients: results from a prospective web-based regional platform Russo, F.P.
 2019
 51 S1 p. e16
 article
69 Magnetic resonance risk score and liver stiffness by transient elastography have complementary prognostic values in patients with Primary Sclerosing Cholangitis Cazzagon, N.
 2019
 51 S1 p. e2
 article
70 MerTK-mediated cytokine secretion mediates a cross-talk between M2c macrophages and hepatic stellate cells (HSC) to induce fibrosis Pastore, M.
 2019
 51 S1 p. e44
 article
71 Metabolomic profile of morbidly obese NAFLD: effect of weight loss by exenatide or diet Patrício, B.
 2019
 51 S1 p. e30
 article
72 Mixed cryoglobulinemia patients with persisting symptoms after SVR are characterized by B-cell clonality markers Lorini, S.
 2019
 51 S1 p. e69
 article
73 Models of care for the management and treatment of hepatitis C virus infection among people who inject drugs Conti, F.
 2019
 51 S1 p. e60-e61
 article
74 NASH-related liver carcinogenesis is critically affected by hypoxia-inducible factor 2α Foglia, B.
 2019
 51 S1 p. e8
 article
75 Necroptosis is associated with a better survival in intrahepatic cholangiocarcinoma Sacchi, D.
 2019
 51 S1 p. e2-e3
 article
76 Nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) patients with advanced liver disease had high burden of comorbidities, healthcare resource utilization (HCRU) and costs: results from Italian administrative databases Marchesini, G.
 2019
 51 S1 p. e27
 article
77 Non-invasive markers of fibrosis at 3 years of follow-up in liver transplant recipients with moderate/severe hepatitis C recurrence, successfully treated with DAAs Martini, S.
 2019
 51 S1 p. e51-e52
 article
78 Novel insights in primary biliary cholangitis (PBC) epidemiology using administrative records Gerussi, A.
 2019
 51 S1 p. e3-e4
 article
79 Novel super stealth immunoliposomes for cancer targeted delivery of doxorubicin: an innovative strategy to reduce liver toxicity Gabbia, D.
 2019
 51 S1 p. e21
 article
80 NS5A gene analysis by next generation sequencing in HCV nosocomial transmission clusters of HCV genotype 1b infected patients Bellocchi, M.C.
 2019
 51 S1 p. e62
 article
81 Nuclear orphan receptor COUP-TF2 induces anoikis resistance, amoeboid migration and metastatic potential in hepatocellular carcinoma (HCC) Ceni, E.
 2019
 51 S1 p. e37
 article
82 Outcome of critically ill patients with cirrhosis and ACLF after ICU admission Ferrarese, A.
 2019
 51 S1 p. e14
 article
83 Overall survival and incidence of liver-related events in a cohort of cirrhotic patients treated with direct antiviral agents: results from a multicenter study Masetti, C.
 2019
 51 S1 p. e57
 article
84 Percutaneous microwave (MW) is superior to radiofrequency ablation (RFA) to induce complete response in cirrhotic patients with very early and early hepatocellular carcinoma (HCC) Mosso, E.
 2019
 51 S1 p. e40
 article
85 PNPLA3 rs738409 C>G variant predicts occurrence of liver-related events and death in non-alcoholic fatty liver Grimaudo, S.
 2019
 51 S1 p. e5-e6
 article
86 Portal endothelial damage in cirrhosis Shalaby, S.
 2019
 51 S1 p. e9-e10
 article
87 Preclinical evaluation of Endothelial Dysfunction by peripheral artery tonometry and its correlations with untargeted metabolomic profiles in NAFLD Troisi, J.
 2019
 51 S1 p. e27-e28
 article
88 Predictors of nosocomial acute-on-chronic liver failure for the risk stratification of patients with cirrhosis admitted to hospital with acute decompensation Zaccherini, G.
 2019
 51 S1 p. e42
 article
89 Pre-liver transplant cardiovascular risk profile and correlation with early post-transplant cardiac events Martini, S.
 2019
 51 S1 p. e52
 article
90 Prevalence and pattern of atherosclerotic changes in primary biliary cholangitis and in non-alcoholic fatty liver disease Ponziani, F.R.
 2019
 51 S1 p. e24
 article
91 Prevalence of patients with non-alcoholic fatty liver disease: from primary care to tertiary centers. The Turin experience Armandi, A.
 2019
 51 S1 p. e29
 article
92 Procoagulant imbalance in chronic hepatitis C and its relationship with cardiovascular and liver damage Sigon, G.
 2019
 51 S1 p. e57
 article
93 Real life data on elbasvir/grazoprevir efficacy, safety and drug-drug interaction profile in patients with chronic hepatitis C viral infection: a prospective analysis in the PITER cohort Quaranta, M.G.
 2019
 51 S1 p. e61
 article
94 Real-life effectiveness and safety of Glecaprevir/Pibrentasvir in HCV infected patients with chronic kidney disease Aglitti, A.
 2019
 51 S1 p. e66
 article
95 Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience Di Maio, V.C.
 2019
 51 S1 p. e53-e54
 article
96 Response to treatment and mortality in patients with acute-on-chronic liver failure according to the new definition of hepatorenal syndrome: a single center 3-year retrospective analysis Giovo, I.
 2019
 51 S1 p. e44
 article
97 Risk factors associated with NASH in obese people who underwent bariatric surgery Raimondo, G.
 2019
 51 S1 p. e6
 article
98 Risk of liver disease in first-degree relatives of patients with advanced NAFLD: initial data from an Italian cohort study Cespiati, A.
 2019
 51 S1 p. e23
 article
99 Role of Bisphenol A on cell biology: effect on proliferation, oxidative stress and steroid hormones metabolism of HepG2 cells Dallio, M.
 2019
 51 S1 p. e46
 article
100 Safety and effectiveness of Regorafenib in recurrent HCC after liver transplantation and progression on Sorafenib: a real-life multicentre study Invernizzi, F.
 2019
 51 S1 p. e12
 article
101 Screening and accelerated vaccination against hepatitis B virus infection in prison: a multicentre pilot study Stasi, C.
 2019
 51 S1 p. e69
 article
102 Screening strategies for Hepatitis C Virus elimination in Italy Kondili, L.A.
 2019
 51 S1 p. e68
 article
103 Selenoprotein P levels discriminate the degree of hepatic steatosis and are related to the NAS score in patients with non-alcoholic fatty liver disease Rosso, C.
 2019
 51 S1 p. e26
 article
104 Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity Scamporrino, A.
 2019
 51 S1 p. e4
 article
105 Shedding light on the X chromosome contribution to the genetic architecture of primary biliary cholangitis Gerussi, A.
 2019
 51 S1 p. e18
 article
106 Surface enhanced Raman spectroscopy as a diagnostic tool for circulating miRNA detection in HCC: the SERMI4cancer project Pascut, D.
 2019
 51 S1 p. e39
 article
107 The administration of a high-fat diet alters bile acid composition and hepatic drug metabolism in rats Gabbia, D.
 2019
 51 S1 p. e22
 article
108 The clinical course of recurrent versus refractory ascites in outpatients with cirrhosis Tonon, M.
 2019
 51 S1 p. e43
 article
109 The development of hepatolocellular carcinoma is not predicted by genetic variants in caucasian compensated HBV cirrhotics treated by Entecavir or Tenofovir for 10 years Loglio, A.
 2019
 51 S1 p. e56
 article
110 The gain of function mutation of SerpinB3 (SCCA-PD) is associated with the severity portal hypertension and complications onset in patients with advanced liver disease Martini, A.
 2019
 51 S1 p. e48
 article
111 The impact of sustained virological response (SVR) on the criteria used to rule out high risk esophageal varices (HRV) in HCV-related compensated advanced chronic liver disease (cACLD) Tosetti, G.
 2019
 51 S1 p. e46-e47
 article
112 The influence of hepatic encephalopathy (HE) history, HE status and neuropsychological test type on learning ability in patients with cirrhosis Zarantonello, L.
 2019
 51 S1 p. e46
 article
113 The integration of Hepatitis B virus into human genome is a common event in the setting of HBeAg negative chronic infection: implications for an altered cell homeostasis and metabolism Salpini, R.
 2019
 51 S1 p. e14
 article
114 The natural history of acute kidney disease (AKD) in patients with cirrhosis Tonon, M.
 2019
 51 S1 p. e10
 article
115 The psychomotor vigilance task: role in the diagnosis of hepatic encephalopathy and relationship with driving ability Formentin, C.
 2019
 51 S1 p. e47
 article
116 The residual native albumin predicts albumin dysfunction and outcomes in hospitalized cirrhotic patients with acute decompensation or acute-on-chronic liver failure Baldassarre, M.
 2019
 51 S1 p. e41
 article
117 The risk of hepatic decompensation is reduced, but not abolished after direct-acting antivirals: the role of spleen stiffness measurement Dajti, E.
 2019
 51 S1 p. e64
 article
118 The role of alcoholic liver disease as risk factor for the development of de novo metabolic syndrome after liver transplantation: a prospective longitudinal study Becchetti, C.
 2019
 51 S1 p. e51
 article
119 The role of bile acids profile and insulin resistance for the prediction of gallbladder disease in a prospective cohort of blood donors Azzaroli, F.
 2019
 51 S1 p. e21
 article
120 The role of delta creatinine and serum albumin in predicting mortality in patients with severe alcoholic hepatitis and infection Germani, G.
 2019
 51 S1 p. e29
 article
121 The role of immune profile in patients with severe alcoholic hepatitis in predicting mortality and the development of infections: a prospective evaluation Germani, G.
 2019
 51 S1 p. e31
 article
122 The role of liver and spleen stiffness measurement in predicting hepatic decompensation after HCV eradication with direct-acting antiviral agents therapy Dajti, E.
 2019
 51 S1 p. e64
 article
123 The time-varying survival benefit of HCC treatment: a multicenter cohort study Vitale, A.
 2019
 51 S1 p. e8
 article
124 Three years of obeticholic Acid (OCA) therapy results in histological improvements in patients with primary biliary cholangitis: further analysis of the POISE Biopsy substudy Bowlus, C.L.
 2019
 51 S1 p. e19
 article
125 Time-varying mHAP III is the most accurate score in predicting survival in patients with hepatocellular carcinoma (HCC) undergoing trans-arterial chemoembolization (TACE) Campani, C.
 2019
 51 S1 p. e6
 article
126 TM6SF2 silencing impairs lipid metabolism and trafficking in HepG2 cells carrying the I148M PNPLA3 variant and MBOAT7 deletion Longo, M.
 2019
 51 S1 p. e25
 article
127 Transcriptomics highlights interleukin-32 a novel biomarker showing higher accuracy in carriers of the pnpla3 i148m variant Baselli, G.A.
 2019
 51 S1 p. e30-e31
 article
128 Treatment of 320 genotype 3 cirrhotic patients with 12 weeks Sofosbuvir/Velpatasvir with or without ribavirin: real life experience from Italy Pasulo, L.
 2019
 51 S1 p. e16-e17
 article
129 Uncovering “hidden” mutations in hepatocellular carcinoma: the use of droplet digital PCR to detect TERT promoter mutations Pezzuto, F.
 2019
 51 S1 p. e37
 article
130 Very low prevalence of active HCV infection among healthcare workers in a regional reference hospital of Tuscany, Italy Colombatto, P.
 2019
 51 S1 p. e63
 article
131 Weighted gene co-expression network analysis of circulating miRNAs as a tool to discover prognostic biomarkers for hepatocelluar carcinoma Pascut, D.
 2019
 51 S1 p. e33
 article
                             131 results found
 
 Koninklijke Bibliotheek - National Library of the Netherlands